rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2015-11-2-177-181rpcardio-146Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯA SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICEСЕЛЕКТИВНЫЙ АНТАГОНИСТ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ ЭПЛЕРЕНОН В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕГегенаваБ. Б.GegenavaB. B.

д.м.н., профессор, зам. директора по научной и инновационной деятельности Научно-образовательного клинического центра инновационной терапии, профессор кафедры пропедевтики внутренних болезней, руководитель отделения кардиологии Университетской клинической больницы №2

119991, Москва, ул. Трубецкая, 8, стр. 2

Trubetskaya ul. 8-2, Moscow, 119991 Russia

ДрапкинаО. М.DrapkinaO. M.

врач-терапевт лечебно-диагностического отделения №4 Университетской клинической больницы №2, аспирант кафедры пропедевтики внутренних болезней

119991, Москва, ул. Трубецкая, 8, стр. 2

Trubetskaya ul. 8-2, Moscow, 119991 Russia

drapkina@bk.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation201523092015112177181Copyright © Gegenava B.B., Drapkina O.M., 20152015Гегенава Б.Б., Драпкина О.М.Gegenava B.B., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/146

The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.

Рассматривается роль альдостерона в патофизиологических процессах. Анализируются эффекты селективного антагониста минералокортикоидных рецепторов эпле-ренона. Обсуждаются преимущества эплеренона в сравнении со спиронолактоном.

альдостеронсердечная недостаточностьфибрилляция предсердийхроническая почечная недостаточностьальбуминурияэплеренонспироно-лактонгинекомастияaldosteroneheart failureatrial fibrillationchronic renal failurealbuminuriaeplerenonespironolactonegynecomastiaReferencesPitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 21: 1658-65.Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 21: 1658-65.Laragh JH. Aldosterone in fluid and electrolyte disorders: Hyper and hypoaldosteronism. J Clin Dis 1960;11:292-318.Laragh JH. Aldosterone in fluid and electrolyte disorders: Hyper and hypoaldosteronism. J Clin Dis 1960;11:292-318.Laragh JH. Cirrhosis for renal-adrenal interaction from studies in hypertension and in failure: Vasopressin, aldosterone, and angiotensin II: further evidence hormones and the pathogenesis of congestive heart. Circulation 1962;25:1015-23.Laragh JH. Cirrhosis for renal-adrenal interaction from studies in hypertension and in failure: Vasopressin, aldosterone, and angiotensin II: further evidence hormones and the pathogenesis of congestive heart. Circulation 1962;25:1015-23.O’Neil RG, Hayhurst RA. Sodium-dependent modulation of the renal Na-K-ATPase: Influence of mineralocorticoids on the cortical collecting duct. J Membr Biol 1985;8:169-79.O’Neil RG, Hayhurst RA. Sodium-dependent modulation of the renal Na-K-ATPase: Influence of mineralocorticoids on the cortical collecting duct. J Membr Biol 1985;8:169-79.Brilla CG, Weber KT. Mineral ocorticoid excess, dietarysodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.Brilla CG, Weber KT. Mineral ocorticoid excess, dietarysodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.Brilla CG, Matsubara LS, Weber KT. Anti-aldosteronetreatment and the prevention of myocardial fibrosis in primary and secondary ldosteronism. J Mol Cell Cardiol 1993;25:563-75.Brilla CG, Matsubara LS, Weber KT. Anti-aldosteronetreatment and the prevention of myocardial fibrosis in primary and secondary ldosteronism. J Mol Cell Cardiol 1993;25:563-75.Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26(6 Pt 1):971-8.Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26(6 Pt 1):971-8.Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578-83.Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578-83.Harda E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.Harda E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.Carey RM. Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2010;17: 194-8.Carey RM. Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2010;17: 194-8.Chai W, Garrelds IM, de Vries R, et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005;46:701-6.Chai W, Garrelds IM, de Vries R, et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005;46:701-6.Romagni P, Rossi F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Athero sclerosis 2003;166:345-9.Romagni P, Rossi F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Athero sclerosis 2003;166:345-9.Fujita M, Minamino T, Asanuma H, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005;46:113-7.Fujita M, Minamino T, Asanuma H, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005;46:113-7.Struthers A, Krum H, Williams GH. A comparison of the aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8.Struthers A, Krum H, Williams GH. A comparison of the aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8.Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.Tait JF, Little B, Tait SAS, et al. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965;25:219-28.Tait JF, Little B, Tait SAS, et al. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965;25:219-28.Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15(1):79-87.Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15(1):79-87.Zannad F, McMurray JJV, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364:11-21.Zannad F, McMurray JJV, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364:11-21.Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53:286-90.Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53:286-90.Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 2002;34:1577-84.Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 2002;34:1577-84.Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45.Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45.Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-10.Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-10.McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11:68-76.Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11:68-76.Cohn JN, Anand IS, Latini R, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003;108:1306-9.Cohn JN, Anand IS, Latini R, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003;108:1306-9.Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753-5.Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753-5.Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.I Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9.I Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9.Swedberg K1, Zannad F, McMurray JJ, et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59(18): 1598-603.Swedberg K1, Zannad F, McMurray JJ, et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59(18): 1598-603.Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.Neuberger HR, Mewis C, van Veldhuisen DJ, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007;28: 2568-77.Neuberger HR, Mewis C, van Veldhuisen DJ, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007;28: 2568-77.Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45: 1832-9.Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45: 1832-9.Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62.Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62.Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007:CD005049.Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007:CD005049.Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005;26:2193-9.Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005;26:2193-9.Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010;159:1584-94.Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010;159:1584-94.Remuzzi G, Benigi A and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-96.Remuzzi G, Benigi A and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-96.Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-85.Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-85.Parving HH, Person F, Lewis JB, et al. AVOID Study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46.Parving HH, Person F, Lewis JB, et al. AVOID Study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46.Tsuboi N, Kawamura T, Okonogi H, et al. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 2012;13(1):113-7.Tsuboi N, Kawamura T, Okonogi H, et al. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 2012;13(1):113-7.Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-9.Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-9.Bomback AS, Kshirsagar AV, Amamoo A, et al. Change in proteinuria after adding aldosterone blocker to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.Bomback AS, Kshirsagar AV, Amamoo A, et al. Change in proteinuria after adding aldosterone blocker to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.Bianchi S, Bigazzi R, Campese VM, et al. Antagonist of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.Bianchi S, Bigazzi R, Campese VM, et al. Antagonist of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-9.Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-9.Chrysostomou A, Pedagogos E, MacGregor L, et al. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-62.Chrysostomou A, Pedagogos E, MacGregor L, et al. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-62.Tylicki L, Rutkowski P, Renke M, et al. Triple blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-93.Tylicki L, Rutkowski P, Renke M, et al. Triple blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-93.Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.Ahn JH, Hong HC, Cho MJ, et al. Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats. Diabetes & Metabolism Journal 2012;36(2):128-35.Ahn JH, Hong HC, Cho MJ, et al. Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats. Diabetes & Metabolism Journal 2012;36(2):128-35.Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17:1362-72.Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17:1362-72.Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-76.Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-76.Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-36.Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-36.Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-42.Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-42.Van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92.Van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92.Lee MY, Shim MS, Kim BH, et al. Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J 2011;35:130-7.Lee MY, Shim MS, Kim BH, et al. Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J 2011;35:130-7.Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009;24:73-84.Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009;24:73-84.Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol 1987;10:198-220.Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol 1987;10:198-220.Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.

The authors declare that there are no conflicts of interest present.